Signal12 readies phase 3 trials for transappendageal forehead delivery of dry eye therapy
Click Here to Manage Email Alerts
Spencer Trask & Co. announced the launch of Signal12, a clinical-stage dry eye company that plans to advance Pro-ocular for the treatment of dry eye disease, according to a press release.
Pro-ocular, licensed from Glia LLC, uses transappendageal forehead delivery to treat dry eye disease by targeting the ophthalmic branch of the trigeminal nerve, according to the release. Twice-daily application to the forehead may eliminate the need for eye drops.
Image: Adobe Stock
The treatment previously demonstrated safety and effectively reduced signs and symptoms of dry eye disease in three phase 2 clinical studies.
Thomas Mitro, former president and chief operating officer of Aerie Pharmaceuticals, will serve as president and CEO of Signal12. Vicente Anido, PhD, Robert Dempsey, James Mazzo, Kenneth Sawyer and Kevin Kimberlin, along with Mitro, make up the board of directors.
“I am honored to lead Signal12 in its mission to transform the landscape of ocular health,” Mitro said in the release. “The company’s pioneering technology and impressive clinical data for Pro-ocular make it a game-changer in treating dry eye disease. I am eager to leverage our team’s extensive experience and push forward with our phase 3 trials. The eye health market is ripe for innovation, and Signal12 will play a crucial role in addressing unmet needs and improving the lives of millions affected by ocular conditions.”
Read more about
Click Here to Manage Email Alerts